For a patient with a metastatic solid tumor in remission on a checkpoint inhibitor who also has R/R multiple myeloma, would you feel comfortable with a bispecific T-cell engager antibody?

The short history of checkpoint inhibitors in myeloma has raised some issues with their use. Of course, in this scenario, they are being employed for other cancers, but they may be instructive nonetheless, especially as it pertains to combination strategies.

1. IMiDs and checkpoint inhibitors don't se...